Pull to refresh
Logo
McKesson agrees to buy Precision Medicine Group in $2.25B deal

McKesson agrees to buy Precision Medicine Group in $2.25B deal

Money Moves

Drug distributor deepens oncology pivot with clinical research and commercialization services

August 25th, 2026: McKesson signs Precision Medicine deal

Overview

Updated Aug 26

The largest US drug distributor, McKesson, agreed on August 25 to buy Precision Medicine Group for $2.25 billion. Precision runs clinical trials, biomarker labs, and payer-negotiation services for biotechnology and pharmaceutical companies.

The purchase is McKesson's biggest bet yet on its two-year pivot from shipping pills to selling oncology services and data. It places the company inside the drug-development pipeline, where margins run far higher than distribution.

Why it matters

As cancer drugs target specific mutations, pharma money is shifting from distribution to clinical services; McKesson just bought a bigger seat at that table.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$2.25B
Deal value for Precision Medicine Group
McKesson's acquisition price, subject to regulatory clearance and customary closing conditions.
$14.2B
Oncology segment quarterly revenue
Latest quarter reported, up 33% year over year on specialty distribution and provider services.
33%
Oncology segment revenue growth
Year-over-year gain in the most recent quarter, fueled by acquisitions like Prism Vision.
3,500
Precision Medicine Group employees
Across two units: CRO Precision for Medicine and commercialization arm Precision AQ.
$2.3B
Blackstone's 2020 valuation
Where the private equity firm took its majority stake in November 2020; the 2026 sale price sits slightly below that mark.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2012 August 2026

6 events Latest: August 25th, 2026 · 3 weeks ago
Tap a bar to jump to that date
  1. McKesson signs Precision Medicine deal

    Latest Acquisition

    McKesson signs a $2.25 billion agreement to buy Precision Medicine Group.

  2. McKesson sells med-surgical stake

    Divestiture

    McKesson sells a minority stake in its medical-surgical unit to Apollo for $1.25 billion.

  3. Prism Vision deal closes

    Acquisition

    McKesson closes the Prism Vision acquisition, adding ophthalmology services.

  4. McKesson targets Prism Vision

    Acquisition

    McKesson announces an $850 million deal for 80% of Prism Vision Holdings.

  5. Blackstone takes majority stake

    Ownership change

    Blackstone buys a majority stake in Precision at a $2.3 billion valuation.

  6. Precision Medicine Group founded

    Founding

    Ethan Leder and Mark Clein launch the company in Bethesda, Maryland.

Scenarios

1

McKesson closes Precision deal, oncology services arm takes shape

Likely Resolves by Q2 2027

Discussed by: Reuters, J.P. Morgan analyst Lisa Gill

The deal clears Hart-Scott-Rodino antitrust review with limited CRO overlap, and McKesson closes by mid-2027. Precision folds into the Oncology & Multispecialty segment, and McKesson cross-sells its services to the biopharma clients that already move products through its distribution network.

2

Antitrust review stalls the deal, regulators demand concessions

Unlikely Resolves by Q2 2027

Discussed by: ecmsource deal analysis

A second request from the Federal Trade Commission or a divestiture demand delays closing beyond a year, or the parties walk away. The ecmsource analysis judged Precision's CRO overlap with existing McKesson affiliates limited, which should help clearance, but the review clock remains the main unknown.

3

McKesson follows with another oncology-services tuck-in

Possible Resolves by Aug 25, 2027

Discussed by: ecmsource deal analysis

McKesson adds more targeted acquisitions in specialty pharmacy, real-world evidence, or community oncology adjacencies within the next year. The analysis described this as likely if McKesson is building a full-stack oncology services platform rather than a one-off purchase.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2014 - March 2015

LabCorp acquires Covance (2015)

LabCorp agreed in late 2014 to buy Covance for about $6.1 billion in cash and stock, pairing its diagnostic-testing network with Covance's clinical trial services. The combined company sold drugmakers lab tests tied to their clinical studies.

Then

The deal closed in March 2015 and made LabCorp a leading provider of clinical trials testing.

Now

It showed a health services company could attach drug-development services to its core business and win higher-margin work.

Why this matters now

Same logic driving McKesson: fold clinical research services into an existing healthcare services base.

April-December 2021

Thermo Fisher acquires PPD (2021)

Thermo Fisher agreed in April 2021 to buy clinical research firm PPD for about $17.4 billion, its largest acquisition ever. The deal combined Thermo's scientific tools with PPD's contract research organization.

Then

Closed in December 2021, adding billions in annual contract research revenue.

Now

Reinforced that scale matters in outsourced drug development and commercialization.

Why this matters now

Shows the size and consolidation of the clinical services market McKesson is entering.

February-July 2021

Icon acquires PRA Health Sciences (2021)

Dublin-based Icon agreed in February 2021 to buy rival PRA Health Sciences for about $12 billion, creating one of the world's largest clinical research organizations.

Then

The deal closed in July 2021.

Now

It was part of a wave of contract research consolidation as pharma outsources more trial work.

Why this matters now

Precision Medicine's CRO unit competes in the same consolidating market McKesson now enters.

Sources

(11)